Watch TRAW. Know when insiders buy.
One email the day a filing lands. Free.
TRAW
Traws Pharma, Inc.
0.55
−0.04 −6.78%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
46
WATCH · shorts 46
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$21.6MNET CASH —52W 0.44 – 3.13SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.2M | −$3.1M | — | -0.16 | −$7.5M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$6.9M | −$7.1M | −133.1% | -0.53 | −$2.6M | — | — | May 15 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$7.4M | −$7.4M | — | -0.71 | −$2.8M | $0 | −$2.8M | Apr 15 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$4.1M | −$4M | — | -0.34 | −$4M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $2.7M | +4694.7% | — | −$1.2M | −$915K | — | -0.11 | −$6M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $57K | +1.8% | — | −$5.2M | $21.5M | — | 2.09 | −$5.4M | — | — | May 15 |
| Q4 2024 · Dec 31derived | $56K | +0.0% | — | −$5.3M | −$29.9M | — | -3.35 | −$4M | $0 | −$4M | Apr 15 |
| Q3 2024 · Sep 30 | $57K | +0.0% | — | −$8.5M | −$8.5M | — | -1.49 | −$11.5M | $0 | −$11.5M | Nov 13 |
| Q2 2024 · Jun 30 | $57K | — | — | −$123.3M | −$123.1M | — | -20.52 | −$9.9M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $56K | — | — | −$5.2M | −$5M | — | -5.92 | −$4.4M | — | — | May 15 |
| Q4 2023 · Dec 31derived | $56K | — | — | −$4.5M | −$4.2M | — | -4.98 | −$4.4M | $0 | −$4.4M | Mar 31 |
| Q3 2023 · Sep 30 | $57K | — | — | −$5.1M | −$4.7M | — | -5.64 | −$4.5M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.8M | — | −$17.9M | $9.2M | 328.7% | 0.82 | −$18.2M | $2.6M | −$20.8M | — | — |
| FY2024 · to Dec 31 | $226K | — | −$142.4M | −$166.5M | -73682.7% | -35.21 | −$29.8M | $3.6M | −$33.4M | — | — |
| FY2023 · to Dec 31 | $226K | — | −$20.3M | −$18.9M | -8384.1% | -22.57 | −$17.9M | $14K | −$17.9M | — | — |
| FY2022 · to Dec 31 | $226K | — | −$19.6M | −$19M | -8391.2% | -0.91 | −$16.3M | — | — | — | — |
| FY2021 · to Dec 31 | $226K | — | −$16.5M | −$16.2M | -7151.8% | -0.96 | −$19.5M | — | — | — | — |
| FY2020 · to Dec 31 | $231K | — | −$25M | −$25.2M | -10890.5% | -2.17 | −$23.1M | $15K | −$23.1M | — | — |
Every number comes from Traws Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.